A carregar...
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...
Na minha lista:
| Publicado no: | BMC Ophthalmol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://ncbi.nlm.nih.gov/pubmed/30537942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-018-0978-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|